Web resources for HIV-1 genotypic-resistance test interpretation

HIV Treat Bull - Vol. 7, No. 6, June 2006

An article in the 15 April issue of Clinical Infectious Diseases, by Tommy Lui from US Division of Infectious Diseases, and and Robert Shafer from Stanford University, usefully describes the scientific principles of HIV-1 genotypic-resistance test interpretation and the most commonly used Web-based resources for clinicians ordering genotypic drug-resistance tests.

Prospective controlled studies have shown that patients whose physicians have access to drug-resistance data, particularly genotypic-resistance data, respond better to therapy than control patients of physicians without such access.

However, interpreting the results of HIV-1 genotypic drug-resistance tests is one of the most difficult tasks facing clinicians caring for HIV-1-infected patients because of the complex interactions among the many mutations that contribute to drug resistance; the varying levels of reduced susceptibility caused by these mutations; and the inability of drug-resistance tests to detect minor, yet clinically relevant, drug-resistant variants in a patient’s virus quasispecies.

Web sites providing HIV-1 resistance summaries:

International AIDS Society, USA

Expert summary of the most clinically relevant mutations.

HIV Sequence Database, Los Alamos National Laboratories

Summary of nearly all HIV-1 mutations associated with in vitro or in vivo drug resistance

Searchable form of Los Alamos summary.

Stanford University HIV Drug Resistance Database

http://hivdb.stanford.edu/cgi-bin/NRTIResiNote.cgi

http://hivdb.stanford.edu/cgi-bin/NNRTIResiNote.cgi

Graphical summaries of PI, NRTI and NNRTI drug-resistance mutations, respectively

Antiretroviral drug summaries by drug

Drug-resistance mutation phenotypic data

Summary of published studies linking baseline genotype and virologic response to a new treatment regimen.

Ref: Liu TF, Shafer RW. Web resources for HIV-1 genotypic-resistance test interpretation. Clinical Infectious Diseases 2006;42:1608-1618.

2006-06-10
IB060706-29

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.